“p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities”.Molecular Cell2(3): 305–16.(September 1998).doi:10.1016/S1097-2765(00)80275-0.PMID9774969.
“Cloning and functional analysis of human p51, which structurally and functionally resembles p53”.Nature Medicine4(7): 839–43.(July 1998).doi:10.1038/nm0798-839.PMID9662378.
“p53CP is p51/p63, the third member of the p53 gene family: partial purification and characterization”.Carcinogenesis22(2): 295–300.(February 2001).doi:10.1093/carcin/22.2.295.PMID11181451.
“DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development”.Cancer Research63(10): 2351–7.(May 2003).PMID12750249.
“PERP-ing into diverse mechanisms of cancer pathogenesis: Regulation and role of the p53/p63 effector PERP”.Biochim Biophys Acta Rev Cancer1874(1): 188393.(Dec 2020).doi:10.1016/j.bbcan.2020.188393.PMID32679166.
“p63 as a complementary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions”.The Medical Journal of Malaysia62(1): 36–9.(March 2007).PMID17682568.
“Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate”.The American Journal of Surgical Pathology31(6): 889–94.(June 2007).doi:10.1097/01.pas.0000213447.16526.7f.PMID17527076.
“Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach”.Modern Pathology18(1): 111–8.(January 2005).doi:10.1038/modpathol.3800251.PMID15309021.
Martin SE, Temm CJ, Goheen MP, Ulbright TM, Hattab EM(2011).“Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study.”.Mod Pathol24(10): 1320–6.doi:10.1038/modpathol.2011.89.PMID21623385.
“P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome”.The Journal of Biological Chemistry278(26): 23906–14.(June 2003).doi:10.1074/jbc.M300746200.PMID12692135.
“Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans”.Trends in Molecular Medicine8(3): 133–9.(March 2002).doi:10.1016/S1471-4914(01)02260-2.PMID11879774.
“P63 gene mutations and human developmental syndromes”.American Journal of Medical Genetics112(3): 284–90.(October 2002).doi:10.1002/ajmg.10778.PMID12357472.